Featured News

The Celiac Disease Foundation is proud to announce its sponsorship of the April 17th University of Chicago’s Celiac Disease & The Continuum of Care Virtual CME Symposium.

9 Meters Biopharma, Inc., a clinical-stage company focused on rare and unmet needs in gastroenterology, announced their collaboration with the Celiac Disease Foundation to support clinical trial enrollment.

For the second consecutive year, the Celiac Disease Foundation hosted the Patient Education & Advocacy Summit.

The Celiac Disease Foundation is proud to have been involved by recruiting patients essential for this trial’s success.

The Celiac Disease Genomic Environmental Microbiome and Metabolomic (CDGEMM) study is revealing how genetic and lifestyle factors make children susceptible to autoimmune diseases such as celiac disease, inflammatory bowel disease, and multiple sclerosis.

Initial findings of the first mass screening study for U.S. children show a high prevalence of celiac disease autoimmunity (CDA) among those without symptoms and no family history of the condition.

The Celiac Disease Foundation achieved a number of critical milestones in 2020 in our efforts to accelerate the development of treatments and a cure for celiac disease.

A new intensive study confirms that people with celiac disease are frequently exposed to gluten in food.

A new Alcohol and Tobacco Tax and Trade Bureau (TTB) ruling released October 13 allows a gluten-free label on spirits distilled from gluten-containing grains.

One of our most important research investments over the last several years has been in iCureCeliac®, the nation’s celiac disease patient registry. This month, researchers published three important studies that used iCureCeliac® as the data source.